Literature DB >> 19053760

Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Daniela Andrei1, Anna E Maciag, Harinath Chakrapani, Michael L Citro, Larry K Keefer, Joseph E Saavedra.   

Abstract

A number of bis(diazeniumdiolates) that we designed to release up to 4 mol of nitric oxide (NO) and that are structural analogues of the NO prodrug and anticancer lead compound O(2)-{2,4-dinitro-5-[4-(N-methylamino)benzoyloxy]phenyl} 1-(N,N-dimethylamino)diazen-1-ium-1,2- diolate (PABA/NO) were synthesized and studied. A majority of these compounds yielded higher levels of NO, were better inhibitors of proliferation of a number of cancer cell lines, and more rapidly induced substantially increased levels of S-glutathionylation of cellular proteins in comparison with PABA/NO. In most cases, the antiproliferative activity and extents of S-glutathionylation correlated well with levels of intracellular NO release. We report bis(diazeniumdiolates) to be a class of S-glutathionylating agents with potent antiproliferative and S-glutathionylating activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053760      PMCID: PMC2629944          DOI: 10.1021/jm800831y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver.

Authors:  J E Saavedra; T R Billiar; D L Williams; Y M Kim; S C Watkins; L K Keefer
Journal:  J Med Chem       Date:  1997-06-20       Impact factor: 7.446

Review 2.  Structure, catalytic mechanism, and evolution of the glutathione transferases.

Authors:  R N Armstrong
Journal:  Chem Res Toxicol       Date:  1997-01       Impact factor: 3.739

Review 3.  Glutathione S-transferases: structure and mechanism of an archetypical detoxication enzyme.

Authors:  R N Armstrong
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1994

4.  "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms.

Authors:  L K Keefer; R W Nims; K M Davies; D A Wink
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

5.  Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide.

Authors:  P J Shami; D L Sauls; J B Weinberg
Journal:  Leukemia       Date:  1998-09       Impact factor: 11.528

Review 6.  Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential.

Authors:  Roberto Scatena; Patrizia Bottoni; Giuseppe E Martorana; Bruno Giardina
Journal:  Expert Opin Investig Drugs       Date:  2005-07       Impact factor: 6.206

Review 7.  An introduction to NO-related therapeutic agents.

Authors:  Gregory R J Thatcher
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

Review 8.  Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities.

Authors:  Larry K Keefer
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

9.  Nitric oxide modulation of human leukemia cell differentiation and gene expression.

Authors:  G Magrinat; S N Mason; P J Shami; J B Weinberg
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

10.  Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells.

Authors:  P J Shami; J O Moore; J P Gockerman; J W Hathorn; M A Misukonis; J B Weinberg
Journal:  Leuk Res       Date:  1995-08       Impact factor: 3.156

View more
  7 in total

1.  Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.

Authors:  Varun Kumar; Sam Y Hong; Anna E Maciag; Joseph E Saavedra; Douglas H Adamson; Robert K Prud'homme; Larry K Keefer; Harinath Chakrapani
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

2.  Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Anna E Maciag; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  Org Lett       Date:  2008-10-29       Impact factor: 6.005

3.  Cross-linking protein glutathionylation mediated by O2-arylated bis-diazeniumdiolate "Double JS-K".

Authors:  Ryan J Holland; Anna E Maciag; Varun Kumar; Lei Shi; Joseph E Saavedra; Robert K Prud'homme; Harinath Chakrapani; Larry K Keefer
Journal:  Chem Res Toxicol       Date:  2012-11-09       Impact factor: 3.739

4.  Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.

Authors:  Rahul S Nandurdikar; Anna E Maciag; Michael L Citro; Paul J Shami; Larry K Keefer; Joseph E Saavedra; Harinath Chakrapani
Journal:  Bioorg Med Chem Lett       Date:  2009-03-28       Impact factor: 2.823

5.  Cellular redox imbalance and changes of protein S-glutathionylation patterns are associated with senescence induced by oncogenic H-ras.

Authors:  Tatiana Armeni; Luisa Ercolani; Lorena Urbanelli; Alessandro Magini; Francesca Magherini; Armanda Pugnaloni; Francesco Piva; Alessandra Modesti; Carla Emiliani; Giovanni Principato
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

6.  Combination of betulinic acid with diazen-1-ium-1,2-diolate nitric oxide moiety donating a novel anticancer candidate.

Authors:  Laiyin Zhang; Shuangxing Hou; Bo Li; Jianjian Pan; Liping Jiang; Guiying Zhou; Hong Gu; Caixing Zhao; Huiping Lu; Fenfen Ma
Journal:  Onco Targets Ther       Date:  2018-01-15       Impact factor: 4.147

7.  2-Acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanylcarbonylamino) phenyl carbamoylsulfanyl] propionic acid, a glutathione reductase inhibitor, induces G2/M cell cycle arrest through generation of thiol oxidative stress in human esophageal cancer cells.

Authors:  Xia Li; Zhiming Jiang; Jianguo Feng; Xiaoying Zhang; Junzhou Wu; Wei Chen
Journal:  Oncotarget       Date:  2017-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.